These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 22739266)
1. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks. Liu XJ; Nowak B; Wang YQ; Plunkett W Chin J Cancer; 2012 Aug; 31(8):373-80. PubMed ID: 22739266 [TBL] [Abstract][Full Text] [Related]
2. Sapacitabine for cancer. Liu X; Kantarjian H; Plunkett W Expert Opin Investig Drugs; 2012 Apr; 21(4):541-55. PubMed ID: 22329458 [TBL] [Abstract][Full Text] [Related]
3. Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC. Liu X; Wang Y; Benaissa S; Matsuda A; Kantarjian H; Estrov Z; Plunkett W Blood; 2010 Sep; 116(10):1737-46. PubMed ID: 20479284 [TBL] [Abstract][Full Text] [Related]
4. Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC. Liu X; Jiang Y; Nowak B; Hargis S; Plunkett W Mol Cancer Ther; 2016 Oct; 15(10):2302-2313. PubMed ID: 27474148 [TBL] [Abstract][Full Text] [Related]
5. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682). Hanaoka K; Suzuki M; Kobayashi T; Tanzawa F; Tanaka K; Shibayama T; Miura S; Ikeda T; Iwabuchi H; Nakagawa A; Mitsuhashi Y; Hisaoka M; Kaneko M; Tomida A; Wataya Y; Nomura T; Sasaki T; Matsuda A; Tsuruo T; Kurakata S Int J Cancer; 1999 Jul; 82(2):226-36. PubMed ID: 10389757 [TBL] [Abstract][Full Text] [Related]
6. Repair of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine-induced DNA single-strand breaks by transcription-coupled nucleotide excision repair. Wang Y; Liu X; Matsuda A; Plunkett W Cancer Res; 2008 May; 68(10):3881-9. PubMed ID: 18483273 [TBL] [Abstract][Full Text] [Related]
7. TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors. Al Abo M; Sasanuma H; Liu X; Rajapakse VN; Huang SY; Kiselev E; Takeda S; Plunkett W; Pommier Y Mol Cancer Ther; 2017 Nov; 16(11):2543-2551. PubMed ID: 28802254 [TBL] [Abstract][Full Text] [Related]
8. 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest. Azuma A; Huang P; Matsuda A; Plunkett W Mol Pharmacol; 2001 Apr; 59(4):725-31. PubMed ID: 11259616 [TBL] [Abstract][Full Text] [Related]
9. Repair of DNA damage induced by the novel nucleoside analogue CNDAG through homologous recombination. Liu X; Jiang Y; Nowak B; Ichikawa S; Ohtawa M; Matsuda A; Plunkett W Cancer Chemother Pharmacol; 2020 Apr; 85(4):661-672. PubMed ID: 32072218 [TBL] [Abstract][Full Text] [Related]
10. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells. Serova M; Galmarini CM; Ghoul A; Benhadji K; Green SR; Chiao J; Faivre S; Cvitkovic E; Le Tourneau C; Calvo F; Raymond E Br J Cancer; 2007 Sep; 97(5):628-36. PubMed ID: 17637678 [TBL] [Abstract][Full Text] [Related]
11. Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations. Liu X; Jiang Y; Nowak B; Qiang B; Cheng N; Chen Y; Plunkett W Cancer Chemother Pharmacol; 2018 Feb; 81(2):255-267. PubMed ID: 29189915 [TBL] [Abstract][Full Text] [Related]
12. Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine. Liu X; Matsuda A; Plunkett W Mol Cancer Ther; 2008 Jan; 7(1):133-42. PubMed ID: 18202016 [TBL] [Abstract][Full Text] [Related]
13. Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine. Muggia F; Diaz I; Peters GJ Expert Opin Investig Drugs; 2012 Apr; 21(4):403-8. PubMed ID: 22404148 [TBL] [Abstract][Full Text] [Related]
14. Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation. Liu X; Guo Y; Li Y; Jiang Y; Chubb S; Azuma A; Huang P; Matsuda A; Hittelman W; Plunkett W Cancer Res; 2005 Aug; 65(15):6874-81. PubMed ID: 16061671 [TBL] [Abstract][Full Text] [Related]
15. Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo. Iizuka K; Zhang C; Eshima K; Jin C; Eshima K; Fukushima M Int J Oncol; 2018 Mar; 52(3):851-860. PubMed ID: 29344636 [TBL] [Abstract][Full Text] [Related]
16. CNDAC-Induced DNA Double-Strand Breaks Cause Aberrant Mitosis Prior to Cell Death. Liu X; Jiang Y; Takata KI; Nowak B; Liu C; Wood RD; Hittelman WN; Plunkett W Mol Cancer Ther; 2019 Dec; 18(12):2283-2295. PubMed ID: 31501277 [TBL] [Abstract][Full Text] [Related]
17. Nucleosides and nucleotides. 141. Chemical stability of a new antitumor nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine in alkaline medium: formation of 2'-C-cyano-2'-deoxy-1-beta-D-ribo-pentofuranosylcytosine and its antitumor activity. Azuma A; Hanaoka K; Kurihara A; Kobayashi T; Miyauchi S; Kamo N; Tanaka M; Sasaki T; Matsuda A J Med Chem; 1995 Aug; 38(17):3391-7. PubMed ID: 7650692 [TBL] [Abstract][Full Text] [Related]
18. Development and biochemical characterization of a 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC)-resistant variant of the human fibrosarcoma cell line HT-1080. Obata T; Endo Y; Tanaka M; Matsuda A; Sasaki T Cancer Lett; 1998 Jan; 123(1):53-61. PubMed ID: 9461018 [TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of sugar-modified cytosine nucleosides. Matsuda A; Sasaki T Cancer Sci; 2004 Feb; 95(2):105-11. PubMed ID: 14965358 [TBL] [Abstract][Full Text] [Related]
20. HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia. Lai TH; Ewald B; Zecevic A; Liu C; Sulda M; Papaioannou D; Garzon R; Blachly JS; Plunkett W; Sampath D Clin Cancer Res; 2016 Jul; 22(14):3537-49. PubMed ID: 26858310 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]